## Summary
The paper introduces **FedTransTEE**, a transformer-based framework for Individual Treatment Effect (ITE) estimation designed to operate across disparate data sources. The method addresses three critical real-world challenges: heterogeneous covariate spaces (different features across sites), disparate treatment sets, and data privacy (via Federated Learning). By utilizing a transformer-based covariate encoder and a cross-attention mechanism between patient and treatment embeddings, the model enables collaborative learning across institutions and supports zero-shot estimation for novel treatments.

## Strengths
- **Handling Heterogeneity:** The framework effectively addresses the "data silo" problem where different hospitals record different variables and administer different treatments. The use of a transformer to process variable-length, named feature sequences is a robust solution to non-aligned feature spaces.
- **Zero-Shot Capability:** By incorporating textual treatment descriptions (encoded via LLMs) into the treatment embedding space, the model can predict outcomes for interventions not seen during training, which is highly relevant for clinical trial planning.
- **Clinical Interpretability:** The authors provide a qualitative analysis of attention maps, validated by a stroke expert, showing that the model focuses on clinically relevant features (e.g., GCS, NIHSS, blood pressure) for specific treatments.
- **Strong Empirical Results:** The model outperforms existing federated ITE baselines (FedCI, iFedTree) and shows competitive performance against centralized state-of-the-art models on both semi-synthetic (IHDP, ACIC, Twins) and complex real-world clinical datasets (ICH, CPAD).

## Weaknesses
### Fatal
None.

### Major
- **Personalized Predictor vs. Global Knowledge:** The architecture uses a local predictor ($f_m$) for each site to handle diverse outcomes. However, in the Federated Learning setting, if a site has a very small sample size for a specific outcome, the local predictor may overfit or fail to converge, potentially negating the benefits of the shared global representation. The paper would benefit from an analysis of how much data is required locally for the personalized head to be effective.
- **Propensity Score/Selection Bias:** While the paper mentions the standard causal assumptions (unconfoundedness, etc.), it does not explicitly detail how it handles selection bias in the federated setting. Traditional ITE methods often use propensity weighting or balanced representations (like CFRNet). It is unclear if the transformer architecture alone is sufficient to mitigate selection bias across sites with different treatment assignment policies.

### Minor
- **Computational Overhead:** Transformers and cross-attention mechanisms are computationally more expensive than the MLP-based architectures (like TARNet) used in baselines. A brief discussion on the trade-off between performance gains and local compute requirements for hospitals would be useful.
- **Zero-Shot Evaluation Scope:** The zero-shot evaluation is limited to the ICH dataset. While promising, the robustness of this feature across more diverse treatment types (e.g., in the CPAD dataset) is not fully explored.

## Nice-to-Haves
- A sensitivity analysis on the number of shared vs. unique covariates to see at what point the "collaboration" benefit diminishes.
- Comparison with a "Global Predictor" version of FedTransTEE to justify the necessity of the personalized predictor $f_m$.

## Novel Insights
The primary novel insight is the application of **tokenized feature-value embeddings** (common in tabular transformers) specifically to the **causal inference** task in a **federated** context. By treating each patient's available measurements as a sequence of "feature-name + value" tokens, the authors bypass the need for fixed-width input vectors, which has been a major bottleneck in multi-center clinical studies. Furthermore, the use of cross-attention between patient state and treatment descriptions to enable zero-shot ITE estimation is a significant conceptual step forward for the field.

## Suggestions
- Clarify whether any representation balancing (e.g., MMD or Wasserstein distance) was used to handle selection bias, or if the authors rely solely on the transformer's capacity.
- Provide a brief ablation study in the final version showing the impact of the "Treatment Information Encoder" versus simple one-hot embeddings for the supervised tasks.

## Score and Decision
The paper addresses a high-impact problem with a technically sound and well-evaluated architecture. The ability to handle heterogeneous feature spaces in a federated manner is a significant contribution to the ML-for-healthcare community.

MY FINAL SCORE: 8.0
MY FINAL DECISION: Accept